申请人:Orszagos "Frederic Joliot-Curie" Sugar-biologiai es Sugaregeszsegugyi
公开号:US05440031A1
公开(公告)日:1995-08-08
The invention relates to partially novel metal complexes, salts and double salts of 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane compounds of the formula (I), ##STR1## wherein Q.sup.1 and Q.sup.2 mean hydrogen or a group of the formula (III), ##STR2## in the groups of the formula (III) the R subtituents independently represent hydrogen, a C.sub.1-5 straight or branched chain alkyl group, a C.sub.2-5 straight or branched chain alkenyl group, phenyl or phenyl-C.sub.1-5 alkyl group, the two latter ones optionally being substituted on their aromatic part by one or more halogen(s), C.sub.1-5 alkyl, C.sub.1-5 alkoxy, cyano or nitro group(s), with the proviso that at least one of Q.sup.1 and Q.sup.2 is other than hydrogen; Me stands for an alkaline metal or alkaline earth metal or transition metal ion; q is 0 or 1; M and N, independently from each other, stand for hydrogen or an alkaline metal, alkaline earth metal or optionally substituted ammonium ion; m, n and p are integers each being equal to the charge of M, N or Me, respectively; s and r are, independently from each other, 0, 1, 2, 3 or 4, with the proviso that (i) r, s and q cannot simultaneously be 0; and (ii) the number of hydrogens in the meaning of M or N may be 0, 1 or 2, which are useful in the decorporation of metal ions such as the radioactive isotopes of strontium or cerium and may be administered intravenously, locally, transdermally or rectally.
该发明涉及1,4,10,13-四氧杂-7,16-二氮杂环十八烷化合物的部分新型金属配合物、盐和双盐,其化学式为(I): ##STR1## 其中,Q1和Q2表示氢或式(III)的基团, ##STR2## 在式(III)的基团中,R取代基独立地表示氢、C1-5直链或支链烷基、C2-5直链或支链烯基、苯基或苯基-C1-5烷基,后两者的芳基部分可以选择地被一个或多个卤素、C1-5烷基、C1-5烷氧基、氰基或硝基取代,但至少有一个Q1和Q2不是氢;Me代表碱金属、碱土金属或过渡金属离子;q为0或1;M和N独立地表示氢或碱金属、碱土金属或可选择地取代的铵离子;m、n和p是整数,分别等于M、N或Me的电荷;s和r独立地为0、1、2、3或4,但须满足:(i) r、s和q不能同时为0;(ii) M或N的氢数可以为0、1或2。这些化合物有助于去除金属离子,如锶或铈的放射性同位素,并可以经静脉、局部、经皮或直肠给予。